Cancer cachexia is a wasting syndrome, which is characterized by a loss in weight, anorexia, asthenia, and anemia. The pathogenicity of this syndrome is multifactorial, due to complex interactions between tumor and host factors. It is among the common manifestation of the advanced malignant disease, leading to death. Some of the symptoms include involuntary weight loss, skeletal muscle wasting, anorexia/loss of appetite, and lowered quality of life. This disease is also observed among patients with diseases, such as AIDS/HIV, heart failure, emphysema, and kidney failure.
This report by Mordor Intelligence provides extensive insights of the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases and status of clinical trials across major regions of the world are provided, with data obtained from multiple sources. The report also includes a list of key sponsors having pipeline products for the concerned market.
The report will cover analysis on trails and information on key sponsors, companies, and researchers.
Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and in-house team of research experts. The pipeline assessment reports are generated, based on the information procured from various stake holders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research are validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports are continuously updated, to incorporate the most relevant and authentic information to our clients.
2. Research Methodology
3. Disease Epidemiology and Trends
4. Healthcare Expenditure and R&D Trends
5. Executive Summary
6. Clinical Trials Segmentation, by Phase
6.1 Phase-III Product Candidates
6.2 Phase-II Product Candidates
6.3 Phase-I Product Candidates
7. Clinical Trials, Segmentation, by Status
7.6 Other Statuses
8. Pipeline Therapeutic Assessment (Infographic Charts and Brief description)
8.1. By Clinical Phase and Molecule Type
8.2. By Clinical Phase and Route of Administration
8.3 By Sponsor/Collaborator/Institutions
8.4 By Geography
9. Market Updates
10. Key Sponsor Profiles
11. Sources and Disclaimer
12. About Mordor Intelligence